tetano
Editor, Senior Moderator
Mol Brain
. 2022 Aug 9;15(1):71.
doi: 10.1186/s13041-022-00956-1.
Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice
Ping Su[SUP] #[/SUP][SUP] 1 [/SUP], Dongxu Zhai[SUP] #[/SUP][SUP] 1 [/SUP], Albert H C Wong[SUP] 1 2 3 4 [/SUP], Fang Liu[SUP] 5 6 7 8 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that has caused a global pandemic Coronavirus Disease 2019 (COVID-19). Currently, there are no effective treatments specifically for COVID-19 infection. The initial step in SARS-CoV-2 infection is attachment to the angiotensin-converting enzyme 2 (ACE2) on the cell surface. We have developed a protein peptide that effectively disrupts the binding between the SARS-CoV-2 spike protein and ACE2. When delivered by nasal spray, our peptide prevents SARS-CoV-2 spike protein from entering lung and olfactory bulb cells of mice expressing human ACE2. Our peptide represents a potential novel treatment and prophylaxis against COVID-19.
Keywords: Angiotensin-converting enzyme 2 (ACE2); COVID-19; Interfering peptide; SARS-CoV-2; Viral entry.
. 2022 Aug 9;15(1):71.
doi: 10.1186/s13041-022-00956-1.
Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice
Ping Su[SUP] #[/SUP][SUP] 1 [/SUP], Dongxu Zhai[SUP] #[/SUP][SUP] 1 [/SUP], Albert H C Wong[SUP] 1 2 3 4 [/SUP], Fang Liu[SUP] 5 6 7 8 [/SUP]
Affiliations
- PMID: 35945596
- DOI: 10.1186/s13041-022-00956-1
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that has caused a global pandemic Coronavirus Disease 2019 (COVID-19). Currently, there are no effective treatments specifically for COVID-19 infection. The initial step in SARS-CoV-2 infection is attachment to the angiotensin-converting enzyme 2 (ACE2) on the cell surface. We have developed a protein peptide that effectively disrupts the binding between the SARS-CoV-2 spike protein and ACE2. When delivered by nasal spray, our peptide prevents SARS-CoV-2 spike protein from entering lung and olfactory bulb cells of mice expressing human ACE2. Our peptide represents a potential novel treatment and prophylaxis against COVID-19.
Keywords: Angiotensin-converting enzyme 2 (ACE2); COVID-19; Interfering peptide; SARS-CoV-2; Viral entry.